IQWiG says Gilead’s anti-HIV drug genvoya offers slightly lower benefits than competition
German Institute for Quality and Efficiency in Health Care (IQWiG) said USdrug maker Gilead’s (Nasdaq: GILD) anti-HIV drug Genvoya provides marginally lower benefit in comparison with the competition, according to an early benefit assessment.
The regulator has said the drug offered minor added benefit for pre-treated women, but not for men.
The drug is indicated if the previous treatment has failed or cannot be continued due to side effects.
The Federal Joint Committee (G-BA) said between four groups of patients depending on age (adolescents/ adults) and previous treatment (pre-treated/ treatment-naive). Genvoya was compared with efavirenz in combination with two other drugs in treatment-naive patients, and with individual antiretroviral therapy in pre-treated patients.
US drug major Bristol-Myers Squibb (NYSE: BMY) markets efavirenz under the brand name Sustiva in the US, the United Kingdom, Ireland, France, Germany, Italy, and Spain.
ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved …
GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines …